CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?

Glioblastoma is aggressive, highly infiltrating, and the most frequent malignant form of brain cancer. With a median survival time of only 14.6 months, when treated with the standard of care, it is essential to find new therapeutic options. A specific CDK4/6 inhibitor, PD0332991, obtained accelerate...

Descripción completa

Detalles Bibliográficos
Autores principales: Schröder, Lisette B. W., McDonald, Kerrie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663246/
https://www.ncbi.nlm.nih.gov/pubmed/26649278
http://dx.doi.org/10.3389/fonc.2015.00259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663246/
https://www.ncbi.nlm.nih.gov/pubmed/26649278
http://dx.doi.org/10.3389/fonc.2015.00259

Ejemplares similares